Die Inhalte stammen aus dem NEJM Journal Watch Oncology & Hematology, der von der NEJM Group, a Division of the Massachusetts Medical Society, hergestellt und veröffentlich wird. Alle Rechte sind vorbehalten und alle Inhalte sind urheberrechtlich geschützt. Universimed und unsere Sponsoren ermöglichen Ihnen den Zugang zu diesen Inhalten als professionelle Unterstützung.
Immunotherapy plus Chemotherapy Before Surgery Improves Outcomes in Lung Cancer
Adding nivolumab to neoadjuvant chemotherapy for patients with operable non–small-cell lung cancer reduced the risk of recurrence.
What Is the Role of Radiotherapy in Early-Stage Lung Cancer?
The use of radiotherapy as a treatment option is increasing, underscoring the need for radiation oncologists to be involved in the multidisciplinary management of patients with pulmonary nodules.
MRI Screening for Spinal Cord Compression in Metastatic Castration-Resistant Prostate Cancer
MRI screening with pre-emptive treatment in asymptomatic patients with evidence of epidural disease did not improve time to development of clinical SCC.
Are Patients Receiving Guideline-Concordant Treatment for Lung Cancer?
Among patients screened for a national trial, rates of such treatment were low, thereby calling into question extrapolation of findings from clinical trials.
DESTINY-Breast03: Improving Outcomes in Metastatic HER2-Positive Breast Cancer
Rates of progression-free survival were significantly higher with trastuzumab deruxtecan than with trastuzumab-emtansine.
Peptide Receptor Radionuclide Therapy for Refractory Mid-Gut Neuroendocrine Tumors
A new study supports prior findings that progression-free survival, but not overall survival, is superior with PRRT versus systemic therapy.
Chronic Lymphocytic Leukemia Resistance to Next-Generation BTK Inhibitors
Some patients treated with pirtobrutinib acquired mutations in Bruton tyrosine kinase binding domains that led to disease progression.
Triplet Therapy for High-Risk Chronic Lymphocytic Leukemia
Treatment with obinutuzumab, ibrutinib, and venetoclax induced high response rates in previously untreated patients.
A Thrombopoietin Receptor Agonist for Chemotherapy-Induced Thrombocytopenia?
Outcomes were not improved with avatrombopag versus placebo.